Enveric's lead candidate EB-003 shows positive preclinical signal in a PTSD fear model

Enveric Biosciences (ENVB) — Enveric Biosciences reported that a single oral dose of EB-003, its non-hallucinogenic neuroplastogen candidate, significantly reduced context-induced freezing behavior in fear-conditioned mice measured one hour post-dose (p<0.05).

The company framed the result as evidence of accelerated extinction of contextual fear, supporting EB-003's potential in PTSD. As an early preclinical readout, it helps build the rationale for advancing the program toward the clinic for a small-cap developer.

Source: biospace.com

For the rest of that week's sector news, read our week in review.